A Manipal hardware startup with a paid-up capital of just ₹1.66 lakh has built cold-chain devices now running in fifteen Indian states and being piloted in Kenya, Nigeria, Tanzania and Fiji. Blackfrog Technologies makes a battery-powered vaccine carrier called Emvólio, and it has spent a decade proving that a company can win national innovation awards almost every year and still stay small on the balance sheet.
That contradiction is the story here. Blackfrog has WHO-standard certification, a Pfizer innovation award announced in 2026, and named backers from a US impact fund to a homegrown venture platform. But its own Registrar of Companies filings show a business that, as of the most recent numbers this piece could verify, was still turning over low single-digit crores in revenue. Deep-tech medical hardware in India, it turns out, can be simultaneously well-regarded and financially tiny — and Blackfrog is a clean illustration of why.
Quick facts
| Company | Blackfrog Technologies Private Limited |
| Founded | 4 November 2015 (incorporation date, Ministry of Corporate Affairs filing via Tofler); some company profiles cite 2017 as the year the product business took shape |
| Founder(s) | Mayur Shetty (CEO) and Donson D’Souza (COO), listed as directors in MCA filings; Ashlesh Bhat is also credited as a co-founder in Inc42’s company profile |
| Businesses | Emvólio portable cold-chain vaccine carriers; Emon Series, a machine-learning monitoring platform for cold-chain infrastructure |
| Latest FY revenue | ₹2.4 crore in FY25 (year to March 2025), up 91.4% year-on-year, as tracked by Inc42’s startup financial database |
| Latest FY profit/loss | Not disclosed in the public filings this piece could access; Tofler’s MCA-sourced summary shows a 58.24% net profit margin for FY23 but withholds the absolute rupee figure behind a paid subscription |
| Listed | Private; not listed on any stock exchange |
| Market value / last valuation | Not publicly disclosed; Tracxn’s own valuation field for the company is masked as of its March 2026 snapshot |
| Key shareholders / backers | Mayur Shetty and Donson D’Souza (promoter-directors); institutional backers include Global Innovation Fund, Next Bharat Ventures, C-CAMP, EDC and Social Alpha |
What they do
Blackfrog Technologies designs and manufactures Emvólio, a backpack-style, battery-powered active-cooling device built to move vaccines, insulin, blood serums and diagnostic specimens across the “last mile” of India’s immunisation supply chain — the stretch between a district cold store and a rural health sub-centre where refrigerated vans do not reach. Each unit holds roughly 30 to 50 vaccine vials (about 300 to 500 doses), weighs around 5.5 kilograms, and holds a 2–8°C range for 12 hours or more on a single charge, with solar-charging variants for areas without reliable power, according to the company’s own product pages and the impact-investment tracker Samridh Health. The company’s customers are government primary and community health centres, immunisation programmes run through state health departments, and international development and health agencies; more recently it has added Emon, a machine-learning platform for remotely monitoring cold-chain equipment, extending the business from single devices toward fleet-level infrastructure.
The origin
The idea traces to a conversation between Mayur Shetty, later Blackfrog’s chief executive, and a former professor about how badly India’s immunisation cold chain broke down at its edges. As Shetty told Tata Trusts’ Horizons magazine in July 2022, the specific trigger was a story about a healthcare worker who carried polio drops to a vaccination camp in an ordinary thermos flask packed with ice cubes that had already half melted by the time she arrived. That image — a life-saving vaccine riding on melting ice and hope — became the design brief for what would eventually become Emvólio: a device that did not depend on ice at all, but on battery-driven active refrigeration with its own temperature log.
A separate account of the company’s founding, published by the Aim2Flourish innovation database, adds a more personal layer: Shetty has also described a family episode in which a nephew received vaccines that had been poorly stored, sharpening his conviction that the problem was systemic rather than isolated to one clinic. Whichever account is emphasised in a given interview, the underlying insight is the same — that India’s vaccination programme was only as strong as its weakest, least-refrigerated link, and that link was usually a health worker with no good tools.
The struggle years
Blackfrog Technologies Private Limited was incorporated on 4 November 2015, according to its Ministry of Corporate Affairs record (CIN U28133KA2015PTC083851, as listed by Tofler). Turning a working prototype into a certifiable medical device took years, and money was tight almost the whole way. In 2018, the company became a portfolio partner of the impact incubator Social Alpha — not primarily for capital, but because, in co-founder Donson D’Souza’s own words to Tata Trusts, “as a young company, we had trouble with our balance sheet, cash-flow management etc.” Social Alpha spent roughly a year working alongside the founders on those basics before later becoming an investor and, eventually, a customer as well.
The company’s own published milestone list, on its corporate site, shows the grinding, competition-by-competition path a hardware startup with little capital has to take to stay alive: a runner-up finish at the CamTech-X medical devices hackathon at Massachusetts General Hospital in 2017; a national win at the Qualcomm Design in India Challenge in March 2020, which came with a cash award and patent-filing support; and three separate prizes at the National Bio-Entrepreneurship Competition in 2019, including a ₹7.5 lakh grant from the WIN Foundation and a USD 100,000 investment opportunity from Social Alpha. Small, non-dilutive wins like these — not a marquee venture round — were how Blackfrog funded its regulatory work, including the ISO 13485 medical-device manufacturing certification and WHO PQS (Performance, Quality and Safety) prequalification it eventually secured, both prerequisites for selling into government immunisation programmes.
The turning point
The moment Blackfrog stopped being a niche vaccine-logistics curiosity and became visible nationally was the Covid-19 pandemic. According to Tata Trusts’ Horizons account, the company gained wide public attention in 2020 when its temperature-controlled carriers were used to transport Covid-19 test specimens in Karnataka — a use case adjacent to, but distinct from, its original routine-immunisation purpose, and one that put its cold-chain integrity claims under a much bigger and more urgent spotlight. Before that moment, Blackfrog’s traction was measured in hackathon prizes and pilot orders; afterward, government health systems and impact funders had a live, high-stakes proof point that the device worked outside a lab.
The scale-up that followed is visible in the deployment numbers Blackfrog and its funding partner Samridh Health published for February 2024: over 600 Emvólio units placed across primary and community health centres, coverage spanning 15 Indian states, more than 700 health workers trained, and roughly 1.6 lakh vaccinations administered through devices in the programme. That is the “after” side of the turning point — a company that had been proving a concept in 2020 was, four years later, running fleet-scale deployment across a large share of the country’s public health geography.
The money behind it
Blackfrog has been funded almost entirely by grants, prizes and impact-oriented seed capital rather than a marquee venture-capital round — consistent with a hardware medtech company selling mostly into government and donor-funded health systems. The startup-data platform Tracxn recorded six funding events for the company running from 2019 through January 2025, with a combined disclosed total of $2.01 million (about ₹19.3 crore at $1≈₹96.0, 18 September 2026); Tracxn masks the individual round sizes and lists 13 total investors.
- Global Innovation Fund — committed $1,000,000 (about ₹9.6 crore) as a pre-Series A investment, according to GIF’s own portfolio page, explicitly earmarked to help Blackfrog convert pilot orders into repeat commercial volume and to develop new product lines.
- Next Bharat Ventures — committed ₹9 crore in seed funding, as disclosed in the fund’s own impact report published in August 2026 (via Entrepreneur India); the same report credits Emvólio with reaching 251,512 beneficiaries in India and states the product now also has a presence in Africa.
- C-CAMP (Centre for Cellular and Molecular Platforms, under the Department of Biotechnology) and EDC — named seed-stage backers in Tracxn’s investor list, dated January 2021 and September 2019 respectively.
- Maharashtra State Innovation Society — provided grant/prize funding in September 2021, per Tracxn.
- Social Alpha — moved from mentor to investor to, per Donson D’Souza, an actual customer, after incubating the company from 2018.
- SAMRIDH (USAID-backed health financing platform) — did not take equity but provided risk guarantees, grants and interest subvention that D’Souza has said were “instrumental” in helping Blackfrog raise commercial working-capital loans from banks.
Because GIF’s disclosed $1 million and Next Bharat Ventures’ disclosed ₹9 crore (roughly $937,000) between them approach or exceed Tracxn’s tracked $2.01 million cumulative figure, the true lifetime total raised is probably somewhat higher than Tracxn’s own aggregate — the two individual disclosures and the aggregate tracker do not fully reconcile, and no source in this research gave a single authoritative lifetime total. No party has published a current valuation for Blackfrog; Tracxn’s own valuation field for the company was masked as of its March 2026 data snapshot.
How it makes money
Blackfrog is fundamentally a hardware seller into public and donor-funded health systems, supplemented by grant and award income that has historically outpaced pure commercial sales.
- Device sales: Emvólio units are priced from roughly ₹54,000 to ₹130,000 depending on the variant (solar-charging capability, battery capacity and monitoring features), per company and partner-published figures — a one-time hardware sale to health departments, NGOs and development agencies rather than a subscription.
- Working-capital-enabled scale: SAMRIDH’s risk guarantees and interest subvention let Blackfrog borrow from commercial banks to fund inventory and manufacturing ahead of government payment cycles — Tofler’s MCA-sourced filing shows a ₹2 crore charge registered with Canara Bank dated 30 September 2023, evidence of exactly this kind of asset-backed borrowing.
- Grants and prize money: A meaningful share of cash into the business over the years has come from non-dilutive sources — government innovation challenges, CSR-linked awards and international competitions — rather than product revenue, which is typical for a certified medical-device maker still building sales volume.
- Emerging software layer: The Emon Series monitoring platform, which uses machine learning to flag cold-chain equipment at risk of failure, points to a second, higher-margin revenue line as the company tries to sell software and services around hardware it has already placed in the field.
- The part people get wrong: observers often assume a startup that wins national innovation awards every year must also be growing revenue at a similar pace. Blackfrog’s own numbers below show the opposite — award recognition and commercial scale have moved on very different timelines.
The numbers
Audited profit-and-loss figures for Blackfrog are not publicly available in full; the company’s MCA filings are summarised by aggregators such as Tofler, which discloses growth rates and margins but paywalls the absolute rupee figures for revenue and profit in most years. Inc42’s startup financial tracker separately discloses two recent years of exact revenue. Both sources are shown below rather than merged, since they cover different periods and were not cross-verified against each other.
| Period | Revenue (₹ crore) | Profit/loss | Source |
| FY23 (year to March 2023) | In the ₹1–10 crore band; up 149.3% year-on-year | Net profit margin reported as 58.24%; absolute figure not disclosed publicly | Tofler, sourced from MCA filings |
| FY24 (year to March 2024) | ₹1.2 crore | Not disclosed | Inc42 startup financial tracker |
| FY25 (year to March 2025) | ₹2.4 crore, up 91.4% year-on-year | Not disclosed | Inc42 startup financial tracker |
- Capital base: Authorised capital ₹15 lakh and paid-up capital just ₹1.66 lakh as of Tofler’s most recent MCA-sourced snapshot — a strikingly small equity base for a company a decade old, reinforcing that growth has been funded through grants, prizes and debt rather than large equity rounds.
- Networth growth: Tofler records networth increasing 1,376.18% in FY23, though again without disclosing the absolute base or ending figures.
- Debt: A ₹2 crore charge with Canara Bank, registered 30 September 2023, is the only secured-borrowing figure visible in public filings.
The revenue swing itself — a jump into the ₹1–10 crore band by FY23, an apparent step-down to ₹1.2 crore in FY24, then a rebound to ₹2.4 crore in FY25 — is exactly the kind of lumpy pattern you would expect from a company whose sales depend on winning individual government tenders and grant-funded pilot programmes rather than recurring commercial contracts.
Where the money comes from
- India, the core market: Emvólio deployment has reached 600-plus devices across primary and community health centres in 15 states as of February 2024, per Samridh Health, and cumulatively 251,512 beneficiaries in India as of Next Bharat Ventures’ August 2026 report.
- Africa expansion: Samridh Health describes a Kenya pilot with letters of intent across four counties including Isiolo and Samburu, undertaken with UNAIDS and WHO partners; a separate profile (The Interview World) states the company’s products have also been procured for use in Nigeria, Tanzania and Fiji through global development agencies, though it gives no unit or revenue figures for these markets.
- Health-worker training as a delivery channel: more than 700 health workers had been trained on the devices as of February 2024 (Samridh Health) — training is bundled with hardware sales rather than sold separately, and is one reason unit economics stay hardware-dominated rather than service-fee-driven.
- The surprise: despite the international headlines around Kenya, Nigeria, Tanzania and Fiji, every revenue figure this piece could verify is domestic — there is no public evidence yet that export markets have moved from pilots and letters of intent into disclosed revenue.
The risks
- Customer concentration in government and donor budgets: because Emvólio’s core buyers are state health departments and donor-funded programmes, Blackfrog’s revenue is exposed to public procurement cycles and grant-funding timelines rather than steady commercial demand — a mechanism directly visible in the FY23-to-FY24 revenue dip recorded by Tofler and Inc42’s trackers.
- Thin equity cushion against a capital-intensive product: medical-hardware manufacturing, certification and inventory are cash-intensive, yet Blackfrog’s paid-up capital is only ₹1.66 lakh per its MCA filing; the company has instead leaned on a ₹2 crore secured bank charge and grant-backed risk guarantees (via SAMRIDH) to fund working capital, which leaves it more exposed to interest-rate and repayment pressure than an equity-funded peer would be.
- Reliance on pilots and non-dilutive funding to reach certification-heavy markets: the company itself has acknowledged, through Global Innovation Fund’s own description of its investment thesis, that a central risk is proving it can “convert pilot projects into larger order volumes” — the same challenge across most of Blackfrog’s award-winning history has been converting recognition into repeat, revenue-generating contracts rather than one-off grants or prizes.
The takeaway
Blackfrog’s decade shows a pattern worth remembering for anyone building hardware for a market that cannot pay full commercial prices: recognition and revenue can move on entirely different clocks. The company collected national innovation awards nearly every year from 2017 onward and built genuine technical credibility — WHO prequalification, ISO 13485 certification, a Pfizer award as recently as 2026 — while its topline stayed in the low crores and its paid-up capital stayed under ₹2 lakh. That is not necessarily a failure; it may be the realistic shape of building a certified medical device for government health systems in a country where the paying customer is a public budget, not a retail consumer. The lesson is to judge such a company on the metric that matches its actual business model — deployment numbers, certifications and grant credibility — rather than assuming that awards translate directly into a scaling commercial balance sheet.
Frequently asked questions
What does Blackfrog Technologies make?
Blackfrog makes Emvólio, a portable, battery-powered active-cooling device for transporting vaccines and other temperature-sensitive medical materials, plus a newer machine-learning monitoring platform called Emon Series for cold-chain equipment.
Who founded Blackfrog Technologies and when?
Blackfrog Technologies Private Limited was incorporated on 4 November 2015, with Mayur Shetty and Donson D’Souza listed as directors in its Ministry of Corporate Affairs filings; some company profiles also credit Ashlesh Bhat as a co-founder.
How much funding has Blackfrog Technologies raised?
Tracxn records six funding events between 2019 and January 2025 totalling a disclosed $2.01 million (about ₹19.3 crore). Separately, Global Innovation Fund has disclosed a $1 million pre-Series A commitment and Next Bharat Ventures has disclosed a ₹9 crore seed investment; these individual figures suggest the true cumulative total may be higher than Tracxn’s tracked aggregate.
Is Blackfrog Technologies profitable?
Full profit-and-loss figures are not public. Tofler’s MCA-sourced data shows a 58.24% net profit margin for FY23 without disclosing the absolute rupee figure, and no profit or loss figure is publicly available for FY24 or FY25.
Where does Blackfrog Technologies operate?
Its core market is India, with over 600 devices deployed across 15 states as of February 2024. It has pilot programmes and letters of intent in Kenya, and its products have reportedly also reached Nigeria, Tanzania and Fiji through global development agencies, though no export revenue figures are public.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Tofler, Blackfrog Technologies Private Limited company and financial summary (MCA filings), accessed September 2026
- Inc42, Blackfrog Technologies company financial profile, accessed September 2026
- Tracxn, BlackFrog Technologies funding rounds and investors profile, accessed September 2026
- Global Innovation Fund, “Blackfrog” portfolio page, accessed September 2026
- Entrepreneur India, “Next Bharat Ventures Portfolio Reaches 2 Mn Lives: Impact Report,” published 29 August 2026
- Tata Trusts Horizons, “Cool as you like,” July 2022
- Samridh Health / Samridh Impact, “Blackfrog Technologies” case study, accessed September 2026 (deployment data as of February 2024)
- Aim2Flourish, “Illuminating Pathways to Health and Sustainability: Emvólio by Blackfrog Technologies,” accessed September 2026
- The Interview World, “Blackfrog: Advancing Intelligent Cold-Chain Innovations,” accessed September 2026
- Blackfrog Technologies Pvt. Ltd., company website “About” and “Company News” pages, accessed September 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.